Gastroesophageal Reflux Disease (GERD) Clinical Trial
Official title:
Prospective and Retrospective Study to Develop a Multi-center Randomized Study, to Determine if Prevention of GERD Related Aspiration by Surgical Fundoplication Improves Lung Allograft Function
The purpose of the prospective study is to collect information surrounding lung transplant
in order to develop a randomized study to determine if prevention of gastroesophageal reflux
disease (GERD) related aspiration (stomach acid coming up from the stomach into the
esophagus) by surgical fundoplication improves lung rejection. Lung transplantation has
evolved into an effective treatment for patients with end-stage lung disease; however, a
significant limitation to long-term survival is patients develop a condition of scarring
known as chronic lung rejection, which can cause lung function to deteriorate, thereby
reducing a patient's chances for survival. Preliminary research has shown a correlation
between the presence of gastroesophageal reflux disease (GERD) and impaired early lung
rejection as assessed by a breathing test, FEV1 (the amount of forced expired air volume in
1 second).
The Investigator is interested in learning more about this condition and the potential for
aspiration (inhaling fluid) injury. The primary goal of this preliminary study will be to
identify aspiration markers that are correlated with adverse clinical outcomes (increased
early rejection, decreased FEV1) that may be used as inclusion criteria for the future
randomized trial.
The purpose of the retrospective study is to collect information surrounding lung transplant
in order to develop a randomized study to determine if prevention of gastroesophageal reflux
disease (GERD) related aspiration (stomach acid coming up from the stomach into the
esophagus) by surgical fundoplication improves lung rejection.
The goal of this retrospective data collection is to review the following:
1. subject outcome event rates for subjects with and without gastroesophageal reflux
disease (GERD) for survival, Bronchiolitis Obliterans Syndrome (BOS), acute rejection
and Forced Expiratory Volume in the first second (FEV-1),
2. the estimated treatment effect of fundoplication on the above event rates,
3. a threshold effect for Bronchiolitis Obliterans Syndrome (BOS) and/or death are more
likely to occur at higher or more proximal acid or non-acid contact times.
This data will be collected in order to better design and coordinate a multicenter
prospective study.
Prospective Group: Approximately 125 Bronchoalveolar Lavage (BAL) samples will be collected
from eligible subjects at the time of clinical bronchoscopies and will be within 2 weeks of
their esophageal study. The Bronchoalveolar Lavage (BAL) samples will be assayed for bile
acids; pepsin, pepsinogen I and II; trypsin; gastrin, and Lipopolysaccharide (LPS) content.
Short-term clinical outcome measures including acute rejection episodes, and Forced
Expiratory Volume in the first second (FEV-1) at one year will be collected. Correlation
between markers of reflux and aspiration will be analyzed.
Retrospective Group: Up to 800 charts within the past 5 years will be reviewed for 1)
subject outcome event rates for subjects with and without Gastroesophageal Reflux Disease
(GERD) for survival, Bronchiolitis Obliterans Syndrome (BOS), acute rejection and Forced
Expiratory Volume in the first second (FEV-1), 2) what is the estimated treatment effect of
fundoplication on the above event rates, 3) is there a threshold effect such that events
such as BOS and death are more likely to occur only at higher or more proximal acid or
non-acid contact times. This review will better address the role of Gastroesophageal Reflux
Disease (GERD) in lung allograft failure, the clinical utility of surgical fundoplication in
preventing lung allograft injury, and the role that acid and non-acid reflux as related to
aspiration causes lung allograft injury as it relates to a wider population.
;
Observational Model: Case-Only
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03561883 -
Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)
|
Phase 3 | |
Completed |
NCT02555852 -
Proton Pump Inhibitors and Risk of Community-acquired Pneumonia
|
N/A | |
Terminated |
NCT01327963 -
Retrospective TIF Study for Treatment of Gastroesophageal Reflux Disease (GERD). The RetroTIF Study
|
N/A | |
Completed |
NCT01570842 -
Anthropometry in Gastroesophageal Reflux Disease and Esophageal Injury
|
N/A | |
Completed |
NCT02141711 -
TAK-438 - Safety, Blood Levels & Effects of Repeated Doses
|
Phase 1 | |
Terminated |
NCT00587275 -
Safety and Efficacy of AST-120 in Patients With GERD Who Continue to be Symptomatic on a Standard Dose of PPI
|
Phase 2 | |
Completed |
NCT00228527 -
Esomeprazole for Treatment of GERD in Pediatric Patients
|
Phase 4 | |
Completed |
NCT00261300 -
Long-term Pantoprazole Trial in Patients With Symptoms of Chronic Acid Peptic Complaints (BY1023/VMG-708)
|
Phase 3 | |
Recruiting |
NCT04506593 -
Indiana University Gastrointestinal Motility Diagnosis Registry
|
||
Completed |
NCT00795093 -
Partial Response to Proton Pump Inhibitors (PPI) Treatment: The Cost to Society and the Burden to the Patient - a Study in the US
|
N/A | |
Completed |
NCT00394472 -
Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients
|
Phase 2 | |
Completed |
NCT00574925 -
Study to Assess Management Strategies for the Use of Esomeprazole (Nexium) in Helicobacter Pylori Infected Patients
|
Phase 4 | |
Terminated |
NCT02749071 -
An Investigation of the EndoStim® Lower Esophageal Sphincter (LES) Stimulation System for the Treatment of Reflux
|
N/A | |
Recruiting |
NCT01129713 -
Comparison of Nexium Versus Secretol in the Healing and Controlling of Symptoms in GERD Patients With Severe EE.
|
Phase 1/Phase 2 | |
Completed |
NCT00734747 -
Safety and Efficacy the Medigus SRS Endoscopic Stapling System in Gastroesophageal Reflux Disease (GERD)
|
Phase 3 | |
Completed |
NCT00312806 -
Effect of Pantoprazole on the Symptoms of Acid Reflux Disease in Adult Patients (BY1023/M3-341)
|
Phase 3 | |
Not yet recruiting |
NCT05579587 -
Transoral Incisionless Fundoplication (TIF) for Laryngopharyngeal Reflux (LPR) Patients
|
||
Recruiting |
NCT02366169 -
Medigus Ultrasonic Surgical Endostapler (MUSE) Registry
|
N/A | |
Completed |
NCT01374074 -
Racial Disparity in Barrett's Esophagus
|
N/A | |
Terminated |
NCT00857597 -
Endoscopic Fundoplication Versus Proton Pump Inhibitors for GERD Treatment
|
Phase 3 |